Tumor lymphocyte and NK cell infiltration and IFNγ upregulation, have been proposed as potential predictors of response alongside mutational burden, however these need to be standardized and widely evaluated in clinical practice (142–144). The gene discussed is IFNG; the disease is neoplasm.